v3.25.2
Shareholders' Equity - Sale of shares (Details)
$ / shares in Units, € in Thousands
1 Months Ended 12 Months Ended
Oct. 31, 2024
shares
Oct. 25, 2024
USD ($)
shares
Oct. 25, 2024
EUR (€)
shares
Oct. 31, 2024
USD ($)
$ / shares
shares
Oct. 31, 2024
EUR (€)
shares
Dec. 31, 2024
shares
Sep. 30, 2024
USD ($)
2024 shelf registration statement              
Disclosure of classes of share capital [line items]              
Maximum offering price in shelf registration statement | $             $ 300,000,000
At the market offerings with Cantor Fitzgerald and Co under shelf registration statement              
Disclosure of classes of share capital [line items]              
Maximum offering price in shelf registration statement | $             $ 75,000,000
Percentage of commission payable for gross proceeds from sales agreement             3.00%
Issue of ordinary shares (in shares)           0  
October 2024 underwritten public offering              
Disclosure of classes of share capital [line items]              
Issue of ordinary shares (in shares)       18,000,000 18,000,000    
Price per share | $ / shares       $ 3.5      
Proceeds from issuing shares       $ 69,790,000 € 64,600    
Payments for share issue costs | €         4,365    
Net proceeds from issuing shares | €         € 60,235    
Underwriters' option in connection to October 2024 underwritten public offering              
Disclosure of classes of share capital [line items]              
Issue of ordinary shares (in shares) 1,940,072            
Duration of underwriters' option       30 days 30 days    
Number of shares callable for options issued 2,700,000     2,700,000 2,700,000    
Share purchase agreement with Eli Lilly and Company              
Disclosure of classes of share capital [line items]              
Issue of ordinary shares (in shares)   3,523,538 3,523,538        
Proceeds from issuing shares   $ 12,300,000 € 11,400        
Purchase price cap, share purchase agreement | $   $ 15,000,000